[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatitis-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatitis-acute":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,43,70,101,126,155,176,203,227,258,280,307,336,365],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100608515","indometacin-with-or-without-aggressive-intravenous-hydration-to-prevent-pancreatitis-after-pancreatic-extracorporeal-shock-wave-lithotripsy-100608515",false,"NCT07202559","Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy","Aggressive Intravenous Hydration With Lactated Ringer's Solution Plus Rectal Indometacin Versus Rectal Indometacin Alone to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy: A Multicentre, Superiority, Randomised, Controlled Trial","Inclusion Criteria:\n\n* Patients with painful chronic pancreatitis eligible for P-ESWL treatment\n* Ages between 18-85 years\n* Providing informed consent\n\nExclusion Criteria:\n\n* Patients readmitted to the hospital for ESWL during the study period\n* contraindications to ESWL\n* Signs of congestive heart failure, such as pitting edema or a New York Heart Association classification greater than class I heart failure. For patients ≥ 70 years old, brain natriuretic peptide (BNP) and cardiac ultrasound would be performed before ESWL. Patients with BNP\\>100pg\u002Fml or Ejection Fraction value\\\u003C50% should be excluded\n* Respiratory insufficiency (pO2 \\\u003C 60 mmHg or saturation \\\u003C 90% despite FiO2 of 30% or requiring mechanical ventilation). For patients ≥ 70 years old, pulmonary function tests would be performed before ESWL. Patients with Forced Expiratory Volume in the first second (FEV1) \\\u003C70% are excluded\n* Patients receiving more than 1.5 mL\u002Fkg\u002Fh or 3 L\u002F24 h of intravenous fluids in the 24 h before ESWL\n* Hypotension (systolic blood pressure \\\u003C90 mmHg or mean arterial pressure \\\u003C70 mmHg)\n* Hypo- or hypernatremia (serum Na+ levels \\\u003C 130 or \\> 150 mmol\u002FL)\n* Severe liver disease (cirrhosis with ascites, liver abscess)\n* receiving NSAIDs within 7 days\n* Contraindications for rectal use of NSAIDs (renal dysfunction with serum creatinine \\>120 μmol\u002FL, allergy, active gastrointestinal bleeding, ulcer disease, and NSAID use for other indications \\[other than cardioprotective aspirin\\])\n* presence of coagulopathy or received anticoagulation therapy within 3 days\n* acute pancreatitis within 3 days\n* known active cardiovascular or cerebrovascular disease\n* pregnant or breastfeeding women\n* without a rectum (ie, status post-total proctocolectomy)","ALL","18 Years","85 Years",{"count":20,"type":21},1250,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to determine whether combining aggressive intravenous hydration with indometacin is more effective at preventing pancreatitis after a Extracorporeal Shock Wave Lithotripsy (ESWL) than using indometacin alone.\n\nThe study will involve patients who are scheduled to undergo ESWL for pancreatic stones. Participants will be randomly assigned to one of two groups: one will receive both the intravenous hydration and the rectal indometacin, while the other will receive only the rectal indometacin.\n\nThe trial will be conducted at multiple centers, ensuring a broad and diverse patient population.\n\nThe primary outcome of the study will be the incidence of pancreatitis after the ESWL procedure.\n\nThis study is important because it could lead to a better understanding of how to prevent pancreatitis after ESWL, potentially improving patient outcomes and reducing the risk of serious complications.",[27,28,29],"Pancreatitis, Chronic","Pancreatitis, Acute","Pancreatic Duct Stones","RECRUITING","2026-04-08",{"date":33,"type":34},"2026-04-13","ACTUAL",{"date":36,"type":34},"2025-10-13",{"date":38,"type":21},"2027-12-01",{"name":40,"class":41},"Changhai Hospital","OTHER",10,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100613482","efferon-lps-hemoadsorption-in-patients-with-acute-pancreatitis-100613482","NCT07267169","Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis","Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Acute Pancreatitis","Inclusion Criteria:\n\n* ≤ 5 days from the onset of acute pancreatitis\n* Acute pancreatitis of moderate or severe according to the Atlanta classification (2012)\n* Acute pancreatitis confirmed by tomography. Modified CTSI Pancreatitis Severity Index Score ≥ 4 points\n* APACHE II \\> 8\n* ≥ 2 points on the Sequential Organ Failure Assessment (SOFA) scale and\u002For ≥ 2 criteria of Systemic Inflammatory Response Syndrome (SIRS):\n* Body temperature ≥ 38 °C or ≤ 36 °C\n* Heart rate ≥ 90\u002Fmin\n* Respiratory rate ≥ 20\u002Fmin or hyperventilation with PaCO₂ ≤ 32 mmHg\n* Leukocytosis (≥ 12,000\u002Fμl) or leukopenia (≤ 4,000\u002Fμl) or left shift of leukocyte formula\n\nExclusion Criteria:\n\n* SOFA score \\> 12 points\n* Presence of an uncontrolled surgical infection focus\n* Development of septic complications - signs of infection\n* Acute pancreatitis as an exacerbation of chronic pancreatitis\n* Blood triglyceride level \\> 1000 mg\u002FdL (11.2 mmol\u002FL)\n* Liver cirrhosis (\\> 6 points by Child-Pugh classification)\n* Unresolved biliary hypertension syndrome\n* BMI ≥ 40\n* Dementia\n* Chronic kidney disease stage 4-5\n* Acute pulmonary embolism confirmed by CT\n* Acute myocardial infarction within the last 4 weeks\n* Acute cerebrovascular accident\n* Severe congestive heart failure\n* Uncontrolled bleeding (acute blood loss within the last 24 hours)","75 Years",{"count":52,"type":21},150,[24],"The goal of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoperfusion using the Efferon® LPS device in combination with hemofiltration (HF) \u002F hemodiafiltration (HDF), with the goal of reducing the severity of organ dysfunction (measured by SOFA score) in patients with acute pancreatitis.\n\nParticipants will be assigned to two groups for comparison: a control group receiving baseline therapy with HF\u002FHDF, and a treatment group receiving baseline therapy in combination with HF\u002FHDF and Efferon® LPS hemoadsorption.The therapy will be initiated within the first 24 hours after ICU admission and within 8 hours after patient enrollment.",[28],[57,58],"acute pancreatitis","hemoperfusion","2026-04-06",{"date":61,"type":34},"2026-04-07",{"date":63,"type":34},"2026-03-30",{"date":65,"type":21},"2028-03-31",{"name":67,"class":68},"Efferon JSC","INDUSTRY",8,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100572186","phase-2-pioglitazone-versus-empagliflozin-for-chronic-pancreatitisrecurrent-acute-pancreatitis-associated-diabetes-mellitus-100572186","NCT06729996","Pioglitazone Versus Empagliflozin for Chronic Pancreatitis\u002FRecurrent Acute Pancreatitis Associated Diabetes Mellitus","Randomized, Parallel Group, Dose Escalation Trial of Pioglitazone Versus Empagliflozin for Chronic Pancreatitis\u002FRecurrent Acute Pancreatitis Associated Diabetes Mellitus: The PEP-DM Trial","PEP-DM","Inclusion Criteria:\n\n1. Age ≥18-80 years at the time of enrollment.\n2. RAP or CP with DM diagnosed before or after CP diagnosis (Confirmed CP on imaging or RAP based on PROCEED study criteria, and confirmed DM as per ADA criteria or clinically diagnosed with DM and on antihyperglycemic therapy)\n3. Able to provide written informed consent and participate in longitudinal follow-up\n4. A Stable retinal exam within 1 year prior to enrollment unless new onset diabetes was diagnosed within 6 months prior to study enrollment. If an eye exam within the past year is not available but the most recent exam is stable, a standard of care eye exam needs to be scheduled during the study period.\n5. HbA1c level 6.5-10.5% at screening visit.\n6. Current ongoing treatment with metformin and\u002For insulin and other antihyperglycemic medications will be accepted at screening. Patients will be willing to safely withdraw one or more study medication or mealtime insulin under the supervision of the study team by the time of screening. The patients clinical team will be informed promptly. Patients not on any antihyperglycemic medications are also eligible.\n\n   a. If on a GLP-1 medication (e.g., semaglutide \\[Ozempic, Wegovy, Rybelsus\\], liraglutide, dulaglutide, exenatide, tirzepatide, etc.), the patient must be on a stable dose for at least 3 months prior to enrollment, with stable weight status at the time of enrollment and the GLP-1 dose cannot be escalated during the study period.\n7. Willing to perform blood glucose and ketone testing on study provided meters as per study protocol.\n\nExclusion Criteria:\n\n1. Inability to take PIO or EMPA due to prior hypersensitivity or allergic reaction or current use of medications with potential for drug-drug interactions (Pioglitazone: Drug information - UpToDate, Empagliflozin: Drug information - UpToDate)\n2. Patients on PIO or EMPA at the time of screening\n3. Diagnosed with Type 1 Diabetes\n4. Pregnancy or lactation in women (positive urine pregnancy test at screening will lead to exclusion)\n5. History of bleeding disorders (e.g., Hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), von Willebrand disease, platelet disorders etc)\n6. Presence of hepatic impairment, ALT \\>3 x ULN with no etiology known at the time of enrollment or any evidence of acute\u002Fchronic liver disease\n7. Ongoing treatment for any malignancy requiring systemic treatment (non-melanoma skin cancers treated in dermatologists' office would be acceptable)\n8. Presence of osteoporosis without definitive treatment according to PI discretion.\n9. Recent inflammatory illness within the 30 days preceding enrollment (e.g.: URTI, episode of AP, etc)\n10. History of heart failure classified by NYHA as Class III or greater\n11. History of kidney dysfunction classified by an eGFR of \\\u003C30 mL\u002Fmin\u002Fmin\n12. Participation in any clinical trial within 30 days before screening for an approved or non-approved investigational medical product.\n13. Active alcohol dependence or chemical dependence including tobacco based on investigator discretion\n14. On a ketogenic diet\n15. Autoimmune pancreatitis, obstructive pancreatitis, and prior surgery of pancreas (Whipple procedure, total pancreatectomy, and distal pancreatectomy)\n16. Any condition which could jeopardize participant safety as per investigator opinion, (hemolytic anemia limiting A1c reliability, any evidence of fluid overload, presence of Congestive heart failure etc).\n17. Recent DKA or signs of decompensated diabetes in last 6 months or increased β hydroxybutyrate levels (\\>0.4 mmol\u002FL) at screening.","80 Years",{"count":80,"type":21},40,[82],"PHASE2","The purpose of this study is to evaluate efficacy of pioglitazone (PIO) versus empagliflozin (EMPA) to improve glycemic control in people with Chronic Pancreatitis (CP) or Recurrent Acute Pancreatitis (RAP) associated with Diabetes Mellitus (DM). To evaluate mixed meal response in PIO versus EMPA group to better understand physiology of both therapies in CP-DM.",[27,28,85],"Diabetes Mellitus",[87,88,89,90,91],"pancreatitis","diabetes","diabetes mellitus","empagliflozin","pioglitazone",{"date":93,"type":34},"2026-04-03",{"date":95,"type":34},"2025-05-29",{"date":97,"type":21},"2027-05-31",{"name":99,"class":41},"Mayo Clinic",2,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100611734","post-ercp-pancreatitis---prophylactic-measures-implementation-study-pep-promis-100611734","NCT07244432","Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS)","Post-ERCP Pancreatitis- Prophylactic Measures Implementation Study","PEP-PROMIS","Inclusion Criteria:\n\n* ERCP in a patient with a native papilla (first ERCP) or repeat ERCP in a patient with previous failed cannulation attempt.\n* Age at least 18 years at the time of ERCP.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Previous papillotomy, papilla dilation, or sphincteroplasty.\n* Rendez-vous cannulation technique.\n* ERCP not performed due to insufficient patient cooperation.\n* ERCP terminated before cannulation due to sedation\u002Fanesthesia-related complications.\n* Failure to reach the Vater's or minor papilla (e.g. duodenal stenosis).\n* Acute biliary pancreatitis.\n* Altered anatomy that prevents reaching the papilla with a standard duodenoscope (e.g. Roux-en-Y).",{"count":110,"type":21},1000,"OBSERVATIONAL","This is a prospective, observational (non-interventional), multicenter study that will look at how often inflammation of the pancreas (called post-ERCP pancreatitis, or PEP) occurs after an endoscopic procedure known as ERCP. The study will take place in several hospitals in Slovakia and Czechia and will include all patients who have this procedure during the study period.\n\nERCP is a common procedure used to treat problems in the bile ducts and pancreas. Although generally safe, it sometimes leads to PEP, which is the most frequent and potentially serious complication. Monitoring the rate of PEP helps doctors evaluate the overall quality of ERCP procedures, since patient safety is an important part of quality care.\n\nThe study will also look at how well hospitals follow current prevention guidelines from two major professional organizations-the European Society of Gastrointestinal Endoscopy (ESGE) and the American Society for Gastrointestinal Endoscopy (ASGE)-and how these prevention methods affect the risk of PEP. This information will help identify how closely real-world practice follows recommended preventive measures and provide new data about PEP rates in the region.",[28,114,115],"ERCP","Prophylaxis","2026-02-18",{"date":118,"type":34},"2026-02-20",{"date":120,"type":34},"2025-12-01",{"date":122,"type":21},"2026-05-31",{"name":124,"class":41},"Branislav Kuncak",1,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":125},"100451592","phase-2-corticosteroids-to-treat-pancreatitis-100451592","NCT05160506","Corticosteroids to Treat Pancreatitis","Corticosteroids to Reduce Inflammation in Severe Pancreatitis: A Randomized, Controlled Study","CRISP","Inclusion Criteria:\n\n1. Adult (≥18 years)\n2. Acute pancreatitis as defined by a clinical diagnosis of pancreatitis and a lipase level ≥3x the upper limit of normal.\n3. Admission or planned admission to an intensive care unit\n4. SOFA disease severity score ≥3 (or at least 3 points above a known baseline)\n\nExclusion Criteria:\n\n1. Known diagnosis of autoimmune pancreatitis\n2. Existing clinical indication for corticosteroids at a dose \\>5mg of oral prednisone daily (or equivalent)\n3. Contraindication to receiving corticosteroids\n4. Protected populations (prisoners)\n5. Pregnancy","99 Years",{"count":136,"type":21},86,[82],"This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.",[140,28,141,142],"Pancreatitis","Corticosteroid","Hydrocortisone",[144,145,146],"Bedside index of severity in acute pancreatitis","Sequential Organ Failure Assessment","Randomized Controlled Trial","2026-02-16",{"date":116,"type":34},{"date":150,"type":34},"2022-03-06",{"date":152,"type":21},"2027-04",{"name":154,"class":41},"Beth Israel Deaconess Medical Center",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":162,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":125},"100525812","incidence-and-clinical-impact-of-serum-hyperamylasemia-poh-after-pancreatectomy-on-postoperative-outcome-and-patient-safety-100525812","NCT06126601","Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety","HYPPO","Inclusion Criteria:\n\n* All patients undergoing pancreatic resection for malignant and benign disease with or without pancreatic anastomosis\n* Patients aged 18-85 years\n* Willingness to participate as demonstrated by giving a written informed consent.\n\nExclusion Criteria:\n\n* Necrosectomy (endoscopic or open) for primary acute pancreatitis or within laparotomy\n* Age less than 18 years\n* Surgical drainage procedures without pancreatic resection (cystojejunostomy for pancreatic pseudocysts)\n* One-stage total pancreatectomy\n* Missing written consent",{"count":52,"type":21},"Recent evidence suggests that postoperative hyperamylasemia (POH) is a predictor of morbidity after pancreatectomy. This is based on the assumption that pancreatitis after pancreatectomy (PPAP) is a major trigger for the development of complications and is indicated by hyperamylasemia. Standardized prospective analysis and correlation with other laboratory parameters, hasn't been performed to date.\n\nTherefore the overall study aims are:\n\n* To prospectively evaluate the incidence and assess the clinical value of biochemical changes for the postoperative course.\n* To confirm and improve the definition and classification of postpancreatectomy acute pancreatitis (PPAP) of the International Study Group of Pancreatic Surgery (ISGPS) and to provide knowledge for effective early management of complications.",[165,166,28],"Pancreatectomy","Hyperamylasemia","2026-02-02",{"date":169,"type":34},"2026-02-03",{"date":171,"type":34},"2023-07-18",{"date":173,"type":21},"2026-07",{"name":175,"class":41},"Technische Universität Dresden",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":190,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":200,"leadSponsor":202,"locationsCount":125},"100606097","phase-2-smoking-cessation-trial-in-recurrent-acute-pancreatitis-and-chronic-pancreatitis-100606097","NCT07171112","Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis","Smoking Cessation Treatment Escalation Among Patients With Recurrent Acute Pancreatitis and Chronic Pancreatitis","Inclusion Criteria\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 18 or older\n* Diagnosed with either recurrent acute pancreatitis or chronic pancreatitis as defined by the American Pancreatic Association:\n\n  o Chronic Pancreatitis (any of the following): i. Moderate\u002Fmarked pancreas imaging morphology (i.e. ductal and parenchymal abnormalities ii. Pancreatic calcifications iii. Histologic confirmation\n\n  o Recurrent Acute Pancreatitis: i. Two or more documented attacks of acute pancreatitis, separated by 3 months from one another, defined by at least 2 of the following 3:\n  1. amylase or lipase values, or both, that are greater than 3 times the upper limit of normal values\n  2. characteristic cross-sectional imaging\n  3. typically upper abdominal pain according to the revised Atlanta classification\n* Currently smoking ≥ 5 cigarettes\u002Fday\n* Explicitly express a desire to quit within 30 days\n* Ability to take oral medication and be willing to adhere to the study intervention regimen\n* Willing and able to comply with trial protocol and follow-up\n\nExclusion Criteria\n\n* Age \\\u003C 18 years\n* Ongoing acute pancreatitis or prior episode of pancreatitis in previous 30 days\n* No desire to quit smoking\n* Currently undergoing smoking cessation intervention (i.e. nicotine replacement therapy, varenicline, counseling, bupropion).\n* Known allergic reactions to varenicline or bupropion SR\n* History of seizures\n* History of an eating disorder (anorexia or bulimia)\n* Closed head trauma with any loss of consciousness or amnesia in the last 5 year\n* Ever history of closed head trauma with \\> 30 minutes of loss of consciousness or amnesia or resulting in skull fracture or subdural hematoma\u002Fbrain contusion\n* Ever history of alcohol withdrawal\n* Ever history of chronic kidney disease (creatine clearance \\\u003C 30 mL\u002Fminute)\n* Liver impairment (i.e. history of cirrhosis) with aminotransferase elevation ≥ 2 times the upper limit of normal and\u002For alkaline phosphatase elevation ≥ 2 times the upper limit of normal.\n* History of bipolar disorder or psychosis\n* Ongoing or recent use (prior 14 days) of any monoamine oxidase inhibitors (isocarboxazid, phenelzine, tranylcypromine, selegiline).\n* Regular use of potent CYP2B6 inhibitors (i.e. clopidogrel, ticlopidine)\n* Regular use of CYP2D6 substrates with narrow therapeutic indices (e.g. flecainide, propafenone, tricyclic antidepressants such as nortriptyline, thioridazine, vinblastine)\n* History of acute angle closure glaucoma\n* Meet criteria for depression as assessed by the Center for Epidemiologic Studies - Depression (CES-D) with a score of 16 or higher.\n* Psychiatric hospitalization within 1 year of screening\n* Participants who have a score of 3 or higher on the Columbus-Suicide Severity Rating Scale (C-SSRS) at enrollment or during any of the study assessments will be excluded\n* Unable to provide consent for self Incarcerated\n* Pregnant females. All female patients of childbearing potential must have a negative pregnancy test and must agree to use highly effective (failure rate \\\u003C1%) contraception during participation in the study.",{"count":184,"type":21},45,[82],"The purpose of this research is to assess the effectiveness of two treatment strategies for smoking cessation in patients with acute recurrent pancreatitis or chronic pancreatitis who smoke cigarettes. All participants will receive varenicline, a commonly used medication that helps people stop smoking, at its standard dose. For those who are unable to stop smoking after 6 weeks of treatment, they will be randomly selected to either 1) increase their dose of varenicline, 2) combine varenicline with bupropion (another medication that helps with smoking cessation) or continue on the standard dose of varenicline. At the end of 12 weeks of treatment, participants will be asked if they have stopped smoking with confirmation done by measuring carbon monoxide levels in their breath.",[27,28,188,189],"Recurrent Acute Pancreatitis","Smoking (Tobacco) Addiction",[191,192,193,194,195],"Smoking cessation","chronic pancreatitis","recurrent acute pancreatitis","varenicline","bupropion","2025-11-06",{"date":198,"type":34},"2025-11-10",{"date":196,"type":34},{"date":201,"type":21},"2028-10-01",{"name":99,"class":41},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":125},"100605925","eus-guided-fnb-induced-pancreatitis-assessment-100605925","NCT07168863","EUS-guided FNB-induced PANCREatitis Assessment","Incidence and Risk Factors of Acute Pancreatitis Following EUS-Guided Fine Needle Biopsy (EUS-FNB)","EUS-PANCREA","Inclusion Criteria:\n\nInpatients and outpatients aged 18 years or older undergoing EUS-guided FNB from a solid or cystic lesion in one of the following locations:\n\n* Pancreas\n* Ampulla of Vater\n* Distal CBD, defined as the intrapancreatic portion of the CBD where the FNB needle passes through the pancreas during biopsy\n\nExclusion Criteria:\n\n* Patients who undergo concurrent ERCP in the same day\n* Patients experiencing an ongoing episode of acute pancreatitis during EUS-FNB\n* Patients undergoing EUS-guided FNA\n* Uncorrectable coagulopathy (INR \\> 1.5)\n* Uncorrectable thrombocytopenia (platelet \\\u003C 50,000)\n* Decline to participate in the study and sign the informed consent form\n* Patients undergoing EUS-guided FNB from the proximal CBD where the FNB needle does not traverse the pancreas",{"count":212,"type":21},300,"This is a descriptive analytical study to investigate the prevalence and risk factors for pancreatitis after Endoscopic Ultrasonography-guided Fine Needle Biopsy (EUS-FNB) in patients at Shariati Hospital in Tehran. The study aims to identify risk factors for post-FNB pancreatitis to improve clinical protocols, reduce complications and treatment costs, and increase diagnostic accuracy for pancreatic and biliary tract diseases. The study will collect demographic and clinical data from all eligible patients undergoing EUS-guided FNB during the study period. Amylase and lipase levels will be measured in all enrolled patients 24 hours post-procedure. Pancreatitis will be diagnosed based on abdominal pain and amylase or lipase levels exceeding three times the normal range 24 hours after the procedure. The outcomes will be independently adjudicated by an expert gastroenterologist not involved in the EUS procedures by reviewing participants' medical records. The consensus definition will be applied as a diagnostic framework (rather than a strict definition) so that the adjudicator can use their best judgment in cases that does not strictly satisfy the criteria. The patients will be contacted 24-72 h after the procedure to follow-up on any potential complications. The study plans to enroll at least 300 patients.",[28,215],"EUS Guided Biopsy",[57,217],"EUS-guided FNB","2025-09-12",{"date":220,"type":34},"2025-09-15",{"date":222,"type":34},"2025-09-11",{"date":224,"type":21},"2027-03-12",{"name":226,"class":41},"University of Tehran",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":234,"maxAge":17,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":239,"conditions":240,"keywords":246,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":125},"100594803","phase-4-comparison-of-the-effectiveness-of-paracetamol-with-ibuprofen-or-paracetamol-with-metamizole-in-treating-pain-in-acute-pancreatitis-in-children-100594803","NCT07024199","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children: a Randomized Trial","Inclusion Criteria:\n\n* diagnosis of AP according to the INSPPIRE mentioned above criteria,\n* age from 3 to 18 years of age,\n* abdominal pain on admission assessed on the Numerical Rating Scale (NRS) or FLACC \\>= 4 points,\n* no analgesic treatment before enrolment in the study OR the last dose of analgesic drug (paracetamol, ibuprofen, metamizole) taken ≥ 6 hours before enrolment for examination,\n* consent of legal guardians and the child (in the case of patients ≥16 years of age) to participate in the study.\n\nExclusion Criteria - patients:\n\n* who took the last dose of painkiller (paracetamol, ibuprofen, metamizole) \\\u003C 6 hours before entering the study,\n* allergic to acetylsalicylic acid, other NSAIDs, paracetamol, metamizole,\n* with inflammatory bowel disease,\n* with gastrointestinal bleeding and other active bleeding,\n* with gastric and\u002For duodenal ulcer disease,\n* chronically taking paracetamol, NSAIDs, metamizole,\n* with liver failure,\n* with heart failure according to the NYHA II-IV scale,\n* with acute and chronic renal failure,\n* with cancer,\n* whose legal guardians did not consent to participate in the study,\n* who did not consent to participate in the study (applies to patients \\> 16 years of age).","3 Years",{"count":236,"type":21},78,[238],"PHASE4","The aim of the study is to assess the effectiveness and tolerance of pain treatment in AP in children using intravenous paracetamol in combination with ibuprofen or paracetamol in combination with metamizole. The study is prospective, interventional, and randomized.",[28,241,242,243,244,140,245],"Pain, Acute","Pancreatic Disease","Pancreatic Diseases","Gastroenterology","Paediatrics",[57,247,248,87],"acute pain","painkillers","2025-08-18",{"date":251,"type":34},"2025-08-24",{"date":253,"type":21},"2025-09",{"date":255,"type":21},"2027-06-01",{"name":257,"class":41},"Medical University of Warsaw",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":100},"100466180","phase-1-safety-and-tolerability-of-pirfenidone-in-acute-pancreatitis-100466180","NCT05350371","Safety and Tolerability of Pirfenidone in Acute Pancreatitis","Evaluation of Pirfenidone as a Therapy in Patients With Predicted Moderate to Severe Acute Pancreatitis","Inclusion Criteria:\n\n1. Patients 18 - 85 years of age\n2. Admitted to hospital for AP, defined by at least 2 of the following 3:\n\n   1. amylase or lipase values, or both, that are greater than 3 times the upper limit of normal values\n   2. characteristic cross-sectional imaging\n   3. typical upper abdominal pain- acute onset of a persistent, severe, epigastric pain often radiating to the back\n3. Patients identified, approached, and consented to administer study medication or placebo within 48 hours of diagnosis of AP.\n4. Predicted to have MSAP or SAP by presence of one or more of the following criteria\n\n   1. APACHE II ≥ 8\n   2. Modified Glasgow or Imrie score ≥ 3\n   3. CRP \\> 150 mg\u002FdL\n   4. PASS score \\> 140 at or within 48 hrs. of admission\n   5. CT or MRI imaging suggesting pancreatic and\u002For peri-pancreatic necrosis\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 or \\> 85 years\n2. Body weight \\> 200 kg\n3. Presentation to the medical attention \\> 48 h after diagnosis of AP\n4. Inability to recruit, randomize and start the allocated treatment within 48h of start of pain\n5. Ongoing AP or diagnosis of AP in previous 30 days\n6. Chronic pancreatitis\n7. Known hypersensitivity to pirfenidone\n8. AST\u002FALT ≥ 2 times the upper normal limit.\n9. Alkaline phosphatase ≥ 2 times the upper normal limit\n10. Bilirubin higher than upper normal limit\n11. Moderate to severe heart failure and\u002For coronary heart disease (New York Heart Association (NYHA) Functional Class III\u002FIV)\n12. On home oxygen or home mechanical ventilation\n13. Advanced liver disease\n14. Paralytic ileus or significant nausea and vomiting\n15. Chronic Diarrhea\n16. Immunosuppressive disorder or on immunosuppressive medications\n17. Active or advanced malignancy\n18. Known cancer that is end-stage with ongoing palliative care or for which palliative care is appropriate\n19. Known established infection prior to the onset of acute pancreatitis\n20. Known history of infective hepatitis\n21. Known live vaccines or therapeutic infectious agents within one month of admission\n22. Known pregnancy or lactation at the time of admission\n23. Ongoing photosensitivity and rash\n24. Women of childbearing potential who are not on oral or injectable contraceptives or IUDs and do not consent to practice abstinence for period of 4 weeks.\n25. Known to be currently participating in a trial testing any investigational medicinal product or participation in a clinical study involving a medicinal product in the last three months\n26. Alcohol or substance abuse in the past 2 years\n27. Family or personal history of long QT syndrome ( \\> 500 msec)\n28. Medications like fluvoxamine or sildanefil\n29. Significant photosensitivity or new rash\n30. Renal disease with GFR \\\u003C 30\n31. Any condition other than above that, in the opinion of the investigator, is likely to result in the death of the patient within the next 2 years\n32. Any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of pirfenidone",{"count":266,"type":21},60,[268,82],"PHASE1","The goal of the current pilot clinical trial is to evaluate the safety and tolerability of pirfenidone in patients with predicted moderately severe and severe acute pancreatitis. Pirfenidone is currently approved by FDA for the treatment of idiopathic pulmonary fibrosis. Now, over 5 years of data has accumulated demonstrating safety of its use in humans. The investigators' preclinical data suggest that pirfenidone is very effective in reducing the severity of acute pancreatitis in animal models. Following are the objectives of the proposed clinical trial:\n\nPrimary Objective:\n\n* To evaluate the safety and tolerability of pirfenidone, compared to placebo, in patients predicted to have moderately severe or severe AP.\n* To evaluate the efficacy of pirfenidone in reducing the laboratory markers of inflammation and improving patient reported outcome measures.\n\nSecondary Objective:\n\n\\- To evaluate the efficacy of pirfenidone in reducing the severity of acute pancreatitis, as measured by well-defined endpoints.",[28],"2025-07-29",{"date":273,"type":34},"2025-08-01",{"date":275,"type":34},"2023-08-01",{"date":277,"type":21},"2027-02",{"name":279,"class":41},"University of Alabama at Birmingham",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":297,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":302,"leadSponsor":304,"locationsCount":4},"100590808","glucose-levels-in-acute-pancreatitis-and-the-impact-of-insulin-depletion-and-bacterial-endotoxaemia-100590808","NCT06972238","Glucose Levels in Acute Pancreatitis and the Impact of Insulin Depletion and Bacterial Endotoxaemia","A Prospective Observational Study of Acute Pancreatitis Severity and the Association of Glucose Time in Range and Stress Hyperglycaemia, Plasma Insulin Depletion and Bacterial Endotoxaemia","GLIDE","Inclusion Criteria:\n\n1. Age 18 years or over\n2. Admission diagnosis of acute pancreatitis (based on Revised Atlanta Criteria)\n3. Ability to provide informed consent in English\n\nExclusion Criteria:\n\n1. Known diabetes mellitus\n2. Use of insulin therapy before admission\n3. Pregnancy\n4. Contraindications to CGM (e.g., allergy to device adhesive)",{"count":289,"type":21},30,"There are currently no early predictive biomarkers for severity of acute pancreatitis (AP) that would allow stratification of patients for potential early interventional therapies. Hyperglycaemia is frequently observed to accompany and contribute to severe AP. However, the underlying mechanism is multifactorial, including in the acute phase of injury, where elevated adrenaline, cortisol and glucagon and inflammatory cytokine-induced insulin resistance all contribute to hyperglycaemia. The investigators propose that the extent of collateral injury of pancreatic β-cells and consequent loss of insulin secretion during the course of acute pancreatitis (AP) underlies disease severity. The investigators will measure plasma C-peptide (as a reliable readout of endogenous insulin), with moment-to-moment glucose monitoring (using subcutaneous continuous glucose monitoring devices), and bacterial endotoxin (lipopolysaccharide (LPS) in a prospective cohort of 30 severe AP patient blood samples taken every 5 days for up to 5 weeks of hospitalization.",[28,292],"Hyperglycaemia",[140,292,294,295,296],"inflammation","clinical severity","beta-cell","NOT_YET_RECRUITING","2025-05-16",{"date":300,"type":34},"2025-05-21",{"date":120,"type":21},{"date":303,"type":21},"2026-08-30",{"name":305,"class":306},"Manchester University NHS Foundation Trust","OTHER_GOV",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":315,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":323,"overallStatus":297,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":125},"100420906","intermittent-fasting-for-pancreatitis-100420906","NCT04760847","Intermittent Fasting for Pancreatitis","Intermittent Fasting as a Primary Means for Improving Quality of Life for Acute and Chronic Pancreatitis","IFPanc","Inclusion Criteria:\n\n* Age ≥ 18 year\n* Recurrent acute pancreatitis defined by greater than 2 episodes of pancreatitis, defined by:\n\nabdominal pain and either amylase or lipase \\> 3 x the upper limit of normal, imaging suggestive of, separated by time\n\n* Anatomy of chronic pancreatitis defined by Rosemont criterion9 or on imaging (CT, MRI)\n* Pancreatic exocrine insufficiency defined by a pancreatic elastase \\\u003C 200 ug\u002Fg stool10\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant Patients\n* Age \\> 80 years\n* Patients who cannot consent for themselves\n* Glycogen storage disease\n* Insulinoma or hypoglycemic state\n* Active alcohol abuse\n* Alcohol induced acute pancreatitis\n* Gallstone induced acute pancreatitis\n* Pancreatic solid neoplasm\n* Patients with diabetes\n* Patients on beta blockers",true,{"count":317,"type":21},64,[24],"The purpose of this research is to compare intermittent fasting with a standard diet approach for improving the quality of life related to your pancreas disease. Our hope is to improve your symptoms and prevent you from needing to go into the hospital for pancreas-related issues.",[140,28,27,321,322],"Pancreas Disease","Acute Recurrent Pancreatitis",[87,57,324,192,325,326],"acute recurrent pancreatitis","fasting","intermittent fasting","2025-04-21",{"date":329,"type":34},"2025-04-22",{"date":331,"type":21},"2026-03",{"date":333,"type":21},"2026-04-01",{"name":335,"class":41},"H. Lee Moffitt Cancer Center and Research Institute",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":346,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":297,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":4},"100564003","phase-2-efficacy-and-safety-of-parecoxib-vs-indomethacin-in-preventing-post-ercp-pancreatitis-100564003","NCT06623513","Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis","A Single-Center, Prospective, Randomized, Controlled, Exploratory Trial Comparing the Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis: The PRECISE Trail","PRECISE","Inclusion Criteria:\n\n* Age between 18 and 80 years.\n* Patients scheduled to undergo ERCP for conditions such as common bile duct stones, benign or malignant biliary strictures, cholangitis, suspected biliary tumors, unexplained jaundice, or pancreas divisum.\n\nExclusion Criteria:\n\n* Previous papillectomy.\n* Previous endoscopic sphincterotomy (EST) without planned pancreatic duct intervention.\n* Simple biliary stent removal or replacement without planned pancreatic duct intervention.\n* Biliary-duodenal fistula, post-biliary-duodenal anastomosis, or post-biliary-jejunal anastomosis.\n* Malignant tumor of the pancreatic head.\n* Currently or recently (within 1 week) suffering from acute pancreatitis.\n* Current or recent (within 1 week) use of NSAIDs.\n* Recent (within 2 weeks) or within 4 weeks prior to surgery, gastrointestinal bleeding or peptic ulcers.\n* History of significant adverse reactions to NSAIDs.\n* Renal insufficiency (creatinine clearance \\< 30 mL\u002Fmin).\n* Moderate to severe hepatic impairment (Child-Pugh score ≥ 7).\n* Severe cardiovascular or cerebrovascular disease.\n* Patients with psychiatric disorders.\n* Pregnant or breastfeeding patients.\n* Patients without a rectum.\n* Patients unwilling or unable to provide informed consent.",{"count":345,"type":21},100,[82],"This study aims to evaluate the efficacy and safety of parecoxib versus indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). It is a single-center, prospective, randomized, controlled, exploratory trial. Participants will be randomly assigned to receive either parecoxib or indomethacin as a preventive treatment. The primary endpoint is to compare the efficacy of the two drugs in reducing the incidence of PEP. Secondary endpoints include the incidence of moderate to severe PEP and post-ERCP-related adverse events. This study will systematically assess the efficacy and safety of both drugs, providing preliminary data for future larger confirmatory trials.",[28,349],"Cholangiopancreatography, Endoscopic Retrograde",[351,352,353,354,355],"Parecoxib","Indomethacin","Post-ERCP Pancreatitis","Efficacy","Safety","2024-09-29",{"date":358,"type":34},"2024-10-02",{"date":360,"type":21},"2024-10-01",{"date":362,"type":21},"2026-09-30",{"name":364,"class":41},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":100},"100443997","quick-large-balloon-dilatation-for-removal-of-large-bile-duct-stones-shodbadi-100443997","NCT05061680","Quick Large Balloon Dilatation for Removal of Large Bile Duct Stones (SHODBADI)","Endoscopic Papillary Short Duration Large Balloon Dilatation for Removal of Large Bile Duct Stones: a Prospective Multicenter Study of Short and Long-term Adverse Events","SHODBADI","Inclusion Criteria:\n\n* Age \\>18 years\n* Common bile duct stone \\>10mm diameter\n\nExclusion Criteria:\n\n* Altered anatomy after surgery (B II, Roux-en-Y reconstruction)\n* Common bile duct cysts\n* Acute pancreatitis\n* Distal common bile duct stricture or tumor\n* Coagulation disorders\n* Ongoing coagulation medication\n* Pregnancy\n* Inability to give an informed consent","95 Years",{"count":375,"type":21},600,[24],"ESGE guidelines suggests 30-60 seconds endoscopic large balloon papillary dilation from the disappearance of the waist of the papilla.\n\nThe investigators have good results in stone removal with much quicker dilatations when the cholangiogram is followed and the dilation is finished as soon as the disappearance of the waist of the papilla is seen. This Scandinavian multicenter prospective study is especially interested in stone clearance rate and short and long-term adverse events such as pancreatitis, cholangitis, bleeding, perforations, residual biliary stones, and newly developing biliary stones.",[28,379,380],"Bleeding","Cholangitis","2023-02-28",{"date":383,"type":34},"2023-03-01",{"date":385,"type":34},"2021-04-05",{"date":387,"type":21},"2026-12-31",{"name":389,"class":41},"Helsinki University Central Hospital"]